Matthew McCormick, MD
Cardiovascular Disease · West Des Moines, IANPI 1922121953
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Pfizer at 29.4% of the total. Reporting peaked in 2019 at $95 and has fallen 77.1% since, to $22 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in IA, where the typical reported total is $1,334.
Across 17 payments — averaging $15.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$79
- E.r. Squibb & Sons, L.L.C.$52
- Novartis$36
- Johnson & Johnson$28
- Itamar Medical Inc$24
- AstraZeneca$16
- plus $35 from 3 others
Across 5 payments — averaging $1211.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$6K
What the payments were for
- Food & beverage$270100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 4 | $79 |
| E.r. Squibb & Sons, L.L.C. | 3 | $52 |
| Novartis | 2 | $36 |
| Johnson & Johnson | 2 | $28 |
| Itamar Medical Inc | 1 | $24 |
| AstraZeneca | 1 | $16 |
| Boston Scientific | 1 | $13 |
| Boehringer Ingelheim | 1 | $12 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $10 |
How this compares
$270 in reported general payments places this provider in the 20th percentile of 142 cardiovascular disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 963 | $749,708 |
| XareltoRivaroxaban | 172 | $165,669 |
| EntrestoSacubitril/Valsartan | 45 | $37,450 |
| Repatha SureclickEvolocumab | 53 | $36,392 |
| BrilintaTicagrelor | 16 | $15,785 |
| JardianceEmpagliflozin | 14 | $9,393 |
| Metoprolol Succinate | 695 | $7,410 |
| Atorvastatin Calcium | 722 | $5,713 |
| Rosuvastatin Calcium | 602 | $4,336 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 23 | $3,739 |
| Valsartan | 148 | $3,230 |
| Ezetimibe-SimvastatinEzetimibe/Simvastatin | 11 | $2,440 |
| Amlodipine Besylate | 515 | $2,354 |
| Ranolazine ErRanolazine | 21 | $1,931 |
| Metoprolol Tartrate | 502 | $1,930 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $79 | $749,708963 claims |
| Johnson & JohnsonXarelto | $28 | $165,669172 claims |
| NovartisEntresto | $36 | $37,45045 claims |
| AstraZenecaBrilinta | $16 | $15,78516 claims |
| Boehringer IngelheimJardiance | $12 | $9,39314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 142 cardiovascular disease providers in Iowa.
Other cardiovascular disease in West Des Moines
- Troy HounshellWest Des Moines$164K
- Enrico MartinWest Des Moines$113K
- Suzanne FeigofskyWest Des Moines$59K
- Robert PaulWest Des Moines$9K
- Lucas GrobenWest Des Moines$6K
- Krishna Theja ReddyWest Des Moines$5K
- Randolph RoughWest Des Moines$3K
- Paul WesleyWest Des Moines$2K
- Brian OlshanskyIowa City$219K
- Gursukhman Deep SidhuDavenport$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.